TY - JOUR
T1 - Tissue Resistance Decrease during Irreversible Electroporation of Pancreatic Cancer as a Biomarker for the Adaptive Immune Response and Survival
AU - Timmer, Florentine E. F.
AU - Geboers, Bart
AU - Scheffer, Hester J.
AU - Bakker, Joyce
AU - Ruarus, Alette H.
AU - Dijkstra, Madelon
AU - van der Lei, Susan
AU - Boon, Rianne
AU - Nieuwenhuizen, Sanne
AU - van den Bemd, Bente A. T.
AU - Schouten, Evelien A. C.
AU - van den Tol, Petrousjka M.
AU - Puijk, Robbert S.
AU - de Vries, Jan J. J.
AU - de Gruijl, Tanja D.
AU - Meijerink, Martijn R.
N1 - Funding Information: M.R.M is a paid consultant for AngioDynamics, Oncology Section Editor for the Journal of CardioVascular and Interventional Radiology by Springer, and President of the Research Committee of the Society of Interventional Oncology and reports research funding, consulting fees, payment or honoraria, and support for attending meetings and/or travel from AngioDynamics; grants from Cancer Center Amsterdam, Adessium Foundation, and Medtronic; and receipt of equipment, materials, drugs, medical writing, gifts, or other services from Bristol Meyer Squibb, AngioDynamics, and Idera. H.J.S., F.E.F.T., T.D.d.G., and B.G. received research funding from AngioDynamics for the conduct of the PANFIRE I/II and III trials and CROSSFIRE trial. J.J.J.d.V. reports support for attending meetings and/or travel from Medtronic. B.G. reports grants from St. Vincents Prostate Cancer Research Center, Cancer Center Amsterdam, and Adessium Foundation; support for attending meetings and/or travel from Urologic Society of Australia and New Zealand; and receipt of equipment, materials, drugs, medical writing, gifts, or other services from Bristol Meyer Squibb, AngioDynamics, and Idera. F.E.F.T. and H.J.S. report grants from Cancer Center Amsterdam and Adessium Foundation; payment or honoraria and from support for attending meetings and/or travel from AngioDynamics; and receipt of equipment, materials, drugs, medical writing, gifts, or other services from Bristol Meyer Squibb, AngioDynamics, and Idera. M.D. and S.N. report support for attending meetings and/or travel from AngioDynamics. R.S.P. reports grant and support for attending meetings and/or travel from Medtronic. T.D.d.G. reports grants from Cancer Center Amsterdam and Adessium Foundation; is cofounder of Lava Therapeutics; is associate editor for Cancer Immunology Research, Journal for ImmunoTherapy of Cancer, and Clinical and Experimental Immunology; is a member of grant review committees of Royal Dutch Cancer Society (KWF) and the Melanoma Research Alliance; is on the board of directors of the Society for the Immunotherapy of Cancer; is on the Advisory board for Lava Therapeutics; holds stock or stock options in Lava Therapeutics; and reports receipt of equipment, materials, drugs, medical writing, gifts, or other services from Bristol Meyer Squibb, AngioDynamics, and Idera. Publisher Copyright: © 2023 SIR
PY - 2023/10
Y1 - 2023/10
N2 - Purpose: To correlate irreversible electroporation (IRE) procedural resistance changes with survival outcomes and the IRE-induced systemic immune response in patients with locally advanced pancreatic cancer (LAPC). Materials and Methods: Data on IRE procedural tissue resistance (R) features and survival outcomes were collected from patients with LAPC treated within the context of 2 prospective clinical trials in a single tertiary center. Preprocedural and postprocedural peripheral blood samples were prospectively collected for immune monitoring. The change (ie, decrease) in R during the first 10 test pulses (ΔR 10p) and during the total procedure (ΔR total) were calculated. Patients were divided in 2 groups on the basis of the median change in R (large ΔR vs small ΔR) and compared for differences in overall survival (OS) and progression-free survival and immune cell subsets. Results: A total of 54 patients were included; of these, 20 underwent immune monitoring. Linear regression modeling showed that the first 10 test pulses reflected the change in tissue resistance during the total procedure appropriately (P < .001; R 2 = 0.91). A large change in tissue resistance significantly correlated with a better OS (P = .026) and longer time to disease progression (P = .045). Furthermore, a large change in tissue resistance was associated with CD8 + T cell activation through significant upregulation of Ki-67 + (P = .02) and PD-1 + (P = .047). Additionally, this subgroup demonstrated significantly increased expression of CD80 on conventional dendritic cells (cDC1; P = .027) and PD-L1 on immunosuppressive myeloid-derived suppressor cells (P = .039). Conclusions: IRE procedural resistance changes may serve as a biomarker for survival and IRE-induced systemic CD8 + T cell and cDC1 activation.
AB - Purpose: To correlate irreversible electroporation (IRE) procedural resistance changes with survival outcomes and the IRE-induced systemic immune response in patients with locally advanced pancreatic cancer (LAPC). Materials and Methods: Data on IRE procedural tissue resistance (R) features and survival outcomes were collected from patients with LAPC treated within the context of 2 prospective clinical trials in a single tertiary center. Preprocedural and postprocedural peripheral blood samples were prospectively collected for immune monitoring. The change (ie, decrease) in R during the first 10 test pulses (ΔR 10p) and during the total procedure (ΔR total) were calculated. Patients were divided in 2 groups on the basis of the median change in R (large ΔR vs small ΔR) and compared for differences in overall survival (OS) and progression-free survival and immune cell subsets. Results: A total of 54 patients were included; of these, 20 underwent immune monitoring. Linear regression modeling showed that the first 10 test pulses reflected the change in tissue resistance during the total procedure appropriately (P < .001; R 2 = 0.91). A large change in tissue resistance significantly correlated with a better OS (P = .026) and longer time to disease progression (P = .045). Furthermore, a large change in tissue resistance was associated with CD8 + T cell activation through significant upregulation of Ki-67 + (P = .02) and PD-1 + (P = .047). Additionally, this subgroup demonstrated significantly increased expression of CD80 on conventional dendritic cells (cDC1; P = .027) and PD-L1 on immunosuppressive myeloid-derived suppressor cells (P = .039). Conclusions: IRE procedural resistance changes may serve as a biomarker for survival and IRE-induced systemic CD8 + T cell and cDC1 activation.
UR - http://www.scopus.com/inward/record.url?scp=85166181782&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.jvir.2023.06.027
DO - https://doi.org/10.1016/j.jvir.2023.06.027
M3 - Article
C2 - 37391072
SN - 1051-0443
VL - 34
SP - 1777-1784.e4
JO - Journal of vascular and interventional radiology
JF - Journal of vascular and interventional radiology
IS - 10
ER -